Last reviewed · How we verify

NCT06812416

Effectiveness of Qualia NAD+ Supplementation on NAD Levels

Completed NA Last updated 6 February 2025
What this trial tests

NA trial testing Qualia NAD+ in Intracellular NAD+ Levels in 92 participants. Completed in 11 March 2024.

Timeline
24 October 2023
Primary endpoint
11 March 2024
11 March 2024

Quick facts

Lead sponsorQualia Life Sciences
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeother
Enrollment92
Start date24 October 2023
Primary completion11 March 2024
Estimated completion11 March 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Qualia Life Sciences

Who can join

Adults 40 to 65, any sex, with Intracellular NAD+ Levels. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current study is designed as a randomized double-blind placebo-controlled parallel trial. It aims to investigate the efficacy of Qualia NAD+ on intracellular NAD levels in blood samples (primary outcomes) and health-related quality of life (secondary outcomes) in an adult population experiencing moderate to severe joint pain between ages of 40 and 65 years.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Qualia NAD+® Increases NAD+ Levels In Human Participants: A Randomized, Double-Blind, Placebo-Controlled Study
    Blomquist SA, Kelly G, Adães S, D’Adamo CR, et al · · 2025 · cited 1× · DOI 10.1101/2025.03.19.25324259

Verify or expand the search:

Other trials of Qualia NAD+

Trials testing the same drug.

Other Qualia Life Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06812416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing